Objective
=========

To investigate the diagnostic value and clinical significance of anti-MCV in pts with early JA.

Patients and methods: 85 pts were included in the study (M/F = 36/49) in the age of 1,5--16 years (mean 8.7 ± 4.9 years). Systemic JA -- 10 pts (11.8%), poly -- 37 (43.5%), oligo-38 (44.7%). Duration of disease was \< 6 months. We studied also 54 pts with early RA, 28 pts with undifferentiated arthritis (UA) and 14 healthy children. Anti-MCV was measured in serum by enzyme-linked immunosorbent assay (ELISA) using the cut off value of 25 U/ml. IgM RF and hsCRP-by laser-nephelometry assay on BN-100 analyser.

Results
=======

Anti-MCV levels were elevated in 23 (27.1%) pts with early JA, in systemic -- 2 (20%), poly -- 11(29.7%), oligo-10 (26.3%). In pts with RF positive JA -- 5 (100%), in RF negative pts- 7(17.1%) (p \< 0.001). In the control groups: 34/54 (62.9%) adults with early RA (p \< 0,001), 14/28 (50%) with UA (p \< 0.05), none of the healthy children showed anti-MCV positivity. The median anti-MCV level in JA was 16.8 U/ml (IR: 11.5--26.4), in RF+ pts (M-834.9; IR 539.3--1149.3 U/ml) was higher than in RF-pts (M-14.5; IR:5.7--22.0 U/ml) (p \< 0.001). Anti-MCV correlated with parameters of disease activity (hs CRP, ESR), with RF and anti-CCP positivity. Anti-MCV were not associated with ANA.

Conclusion
==========

Determination of anti-MCV levels especially together with RF and anti-CCP in pts with early JA can indicate evolution JRA similar RA in adults. Anti-MCV levels correlated with common parameters of inflammation and acute phase response and may be useful to monitor disease activity.
